(Tromsø, 26 April 2019) Biotec Pharmacon’s (“Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has entered into a distribution agreement for Woulgan® with the Austrian distributor Publilog GmbH (Publilog).
Under the terms of the agreement, Publilog becomes an exclusive partner for distribution of Woulgan® to the Austrian market, with Biotec supporting Publilog’s marketing division. Publilog is a subsidiary of the Swiss based Publicare Group – a leading homecare company in the D-A-CH region.
Woulgan® is a premium-priced product targeting hard to heal wounds in the professional wound care market. Clinical experience with Woulgan® demonstrates significantly improved healing, less pain and improved comfort during the treatment period compared to most common therapies.
This agreement align with the newly revised go-to-market strategy for Woulgan®, which focusses on launching and finding new partners in more countries.
Christian Jørgensen, CEO, said:
“We are pleased to see that Woulgan is generating interest in other parts of Europe, building on the increasing success we have been seeing in Germany. By entering into this new distribution agreement, we are delivering on our amended strategy to strenghten Woulgan’s market presence.”
Finn Ketler, VP Wound Care, said:
“By signing Publilog as our exclusive distributor in Austria, our market reach extends beyond our initial core markets. We expect that Woulgan will be reimbursed from January 1st, 2020, subject to regulatory processes, so sales are likely to start having an impact from the end of this year.”
Wolfgang Baumgartner, CEO Publilog GmbH, said
We are proud by signing the contract with Biotec Pharmacon because our intention is to bring new, unique products with high potential for the treatment of chronic wounds to the Austrian market. We started this way two years ago and continue now consistently.